News Bayer pledges $2.2bn to US manufacturing facility Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.
News Bayer names Christoph Koenen as its new CMO Bayer has looked internally for its chief medical officer, appointing Christoph Koenen to the post alongside his current clinical development role.
News Bayer's Kerendia gets broader use in diabetic kidney disease Bayer's fast-growing Kerendia has had its label extended in the US to include chronic kidney disease associated with type 1 diabetes.
News Bayer moves Hyrnuo into frontline lung cancer treatment Bayer chases after Boehringer with an FDA approval for oral HER2 inhibitor Hyrnuo in previously untreated HER2+ lung cancer.
News Bayer's Kerendia on course for NHS use in heart failure Up to 280,000 people with heart failure could soon be eligible for NHS treatment with Bayer's Kerendia, following new NICE guidance.
News Bayer gets €3bn from Apollo for contraceptives unit stake Bayer has partnered with private equity group Apollo to set up a new entity that will handle its long-acting contraceptives products.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.